Everything below concerns Dihexa. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Derived from an angiotensin IV sequence. |
| Appearance | White to off-white powder | Typical for lyophilized research peptides. |
| Solubility | Soluble in dimethyl sulfoxide; sparingly in water | Exact aqueous solubility depends on salt form and purity. |
| Typical storage temperature | -20 °C or below | Desiccated and protected from light for long-term storage. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary in catalog listings. |
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Synthesis via the capping method relies strongly upon a thermodynamically driven template effect; that is, the "thread" is held within the "macrocycle" by non-covalent interactions, for example rotaxinations with cyclodextrin macrocycles involve exploitation of the hydrophobic effect. This dynamic complex or pseudorotaxane is then converted to the rotaxane by reacting the ends of the threaded guest with large groups, preventing disassociation.
== List of virucides == Note that many of the substances, if sold commercially, are usually combinations and mixtures with varying molecular contents. Also note that most products have a limited viricide efficacy. A specific test-protocol is applied. The lists' scope is limited. For further products refer to other lists. Other factors such as stability of the concentrate, application concentration, exposure time, timing of the solution, hydrogen ion concentration (pH value), temperature, etc. play an certain role for the effectivity of a virucide. EPA is providing a public listing called "List N"
East Germany closed itself to the sporting world in May 1965. In 1977 the shot-putter Ilona Slupianek, who weighed 93 kg, failed a test for anabolic steroids at the European Cup meeting in Helsinki and thereafter athletes were tested before they left the country. At the same time, the Kreischa testing laboratory near Dresden passed into government control; it reputedly made around 12,000 tests a year on East German athletes but without any being penalised. The International Amateur Athletics Federation (IAAF) suspended Slupianek for 12 months, a penalty that ended two days before the European championships in Prague. In the reverse of what the IAAF hoped, sending her home to East Germany meant she was free to train unchecked with anabolic steroids, if she wanted to, and then compete for another gold medal, which she won. After that, almost nothing emerged from the East German sports schools and laboratories. A rare exception was the visit by the sports-writer and former athlete, Doug Gilbert of the Edmonton Sun, who said:
== Diagnosis == Substance use disorders can be confused with other psychiatric disorders. There are diagnoses for substance-induced mood disorders and substance-induced anxiety disorders and thus such overlap can be complicated. For this reason, the DSM-IV advises that diagnoses of primary psychiatric disorders not be made in the absence of sobriety (of a duration sufficient to allow for any substance-induced post-acute-withdrawal symptoms to dissipate) up to 1 year.
Sources: en.wikipedia.org
or 140 different polypeptides in the library. This peptide library would be useful for analyzing the effect of the post-translational modification acetylation on lysine which neutralizes the positive charge. Having the library of different peptides at residue 2 and 3 would let the investigator see if some change in chemical properties in the N-terminal tail of the ligated protein makes the protein more useful or useful in a different way.
=== Cell and scaffold-based cartilage regeneration === In order to restore joint cartilage after injury due to chondrocyte loss, cell therapy and chondrocyte replenishment has been shown to work in certain studies. Lying self-assembled MSCs (mesenchymal stem cells) on top of chondrocyte-laden hydrogel scaffolds has shown cell-mediated regeneration of hyaline-like cartilage. However, one drawback of this is that implantation of these scaffolds requires open-joint surgery to gather donor chondrocytes from non-weight-bearing joint cartilage areas. This makes it difficult to apply to the elderly. Along with regenerative therapies there are also several studies that show ways to develop new artificial cartilage.
The N-terminal telopeptide (NTX), also known as amino-terminal collagen crosslinks, is the N-terminal telopeptide of fibrillar collagens such as collagen type I and type II. It is used as a biomarker to measure the rate of bone turnover. NTX can be measured in the urine (uNTX) or serum (serum NTX). The peptide consists of eight amino acids with the sequence YDEKSTGG.
Sources: en.wikipedia.org
As a sign of the expanding commercial ties between the two regions (and Han and Tibetan peoples in particular), a special exhibition was held in Chengdu, so that Sichuanese may see and come into contact with Xikang products. In order to levy taxes from the region, Liu also established a Finance Ministry. Historians and analysts have debated over the effectiveness of these measures. Yang Zhonghua, writing in 1941, praised them as a relatively proactive policy; however, it has been argued by Xie Benzao that Liu's plans, though ambitious on paper, were limited by the realities of war and mostly for the purpose of resource extraction. Another road-building project of Liu Wenhui, constructed in the late 1920s from Yazhou to Chengdu, was known by locals mainly for the ruthlessness of its methods. Despite these projects, Xikang was mostly seen as a rear location distant from the conflicts in Sichuan. Liu encouraged students from Sichuan to take part in "border construction" in Xikang. In September 1929, he set up a newsletter, Bianzheng (邊政), dedicated to frontier administration. The issues of the Bianzheng promoted Sun Yat-sen's Three Principles and advertised Xikang as an attractive region for Chinese settlement, teeming with resources but nonetheless coveted by British imperialists. Propaganda plays published in the newsletter, which can be seen as the official policy of Liu Wenhui's government, exhorted youths to settle and develop the Xikang frontier, despite hardships, and thwart the imperialist plans of Tibet and Britain.
==== Nucleic acid-based molecules ==== Nanogels are advantageous carriers of small, nucleic-acid based molecules that can be employed to treat a variety of diseases. Examples of three different types of molecules that fall into this category, oligonucleotides, miRNA, and nucleoside analogs, are discussed here. In one study, cationic synthetic nanogels modified with insulin and transferrin were synthesized to transport oligonucleotides, a possible therapeutic and diagnostic tool for neurodegenerative disorders, to the brain. These nanogels successfully localized through an in vitro model of the blood-brain barrier and accumulated in the brain in a mouse model. With the treatment of cardiovascular diseases in mind, polysaccharide-based nanogels have been functionalized with fucoidan to target overexpressed P-selectin receptors on platelets and endothelial cells. After loading with miRNA, these nanogels bound to platelets and became internalized by an endothelial cell line. Nanogels have also been used to encapsulate phosphorylated nucleoside analogs, or active forms of anticancer therapeutics. In one study, nanogels loaded with nucleoside 5'-triphosphates underwent surface modifications and successfully bound to overexpressed folate receptors on breast cancer cells. These nanogels were then internalized by the cells and produced a significant increase in cytotoxicity compared to control groups.
== End of the Cold War == After the end of the Revolutions of 1989, Gorbachev and President Bush Sr. met on the neutral island of Malta to discuss the events of the year, the withdrawal of the Soviet military from Eastern Europe, and the future course of their relationship. After their discussions, the two leaders publicly announced they would work together for German reunification, the normalization of relations, the resolution of Third World conflicts, and the promotion of peace and democracy (referred to by President Bush as a "New World Order"). Between the Malta Summit and the Dissolution of the Soviet Union, negotiations on several arms control pacts began, resulting in agreements such as START I and the Chemical Weapons Convention; the latter taking several years to fully implement. Additionally, the United States, still believing the Soviet Union would continue to exist in the long term, began to take steps to create a positive long-term relationship. This new relationship was demonstrated by the joint American-Soviet opposition to Iraq's invasion of Kuwait. The Soviet Union voted in the United Nations Security Council in favor of Resolution 678 authorizing the use of military force against its former Middle Eastern ally. During the late 1980s, several long-running conflicts in the developing world that had been sustained by Cold War rivalry began to wind down, including wars in Cambodia, Angola, and Nicaragua.
In February 2025, Leo Terrell, the chair of the Department of Justice's Task Force to Combat Antisemitism, announced that he would investigate Columbia University, Harvard University, George Washington University, Johns Hopkins University, New York University, Northwestern University, University of California, Berkeley, University of California, Los Angeles, the University of Minnesota, and the University of Southern California as part of the Department of Justice's broader investigation into antisemitism on college campuses. Trump's actions targeting higher education were described as part of an intimidation campaign against institutions viewed as hostile to his political views. He targeted higher education by demanding it give federal oversight of curriculum and targeted activists, legal immigrants, tourists, and students with visas who expressed criticism of his policies or engaged in pro-Palestinian advocacy. Trump froze billions of dollars in federal funding for multiple universities in express defiance of existing laws prohibiting such actions without following proper legal processes that did not happen. The deals and demands made by Trump were criticized as coercive, a shakedown, and legalized extortion in what Axios described as pursuit of a "cultural crackdown". On September 3, Judge Allison D.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.
No major regulatory agency has approved dihexa as a therapeutic product. Human safety and efficacy data are limited. Its sale as a research chemical does not constitute approval for medical use.
Some animal and cell studies report synaptic or cognitive effects, which has led to nootropic framing online. These findings are preliminary and have not been confirmed in robust human trials. The term nootropic is not a regulatory category.
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.